Difference between revisions of "Betrixaban (Bevyxxa)"
(added package insert) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity. | + | Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208383s007lbl.pdf Betrixaban (Bevyxxa) package insert]</ref><ref>[[:File:Betrixaban.pdf | Betrixaban (Bevyxxa) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208383s007lbl.pdf Betrixaban (Bevyxxa) package insert]<ref name="insert"></ref> | |
| + | *[http://www.uptodate.com/contents/betrixaban-patient-drug-information Betrixaban (Bevyxxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/betrixaban-patient-drug-information Betrixaban (Bevyxxa) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| Line 18: | Line 19: | ||
*'''Code name:''' PRT-054021 | *'''Code name:''' PRT-054021 | ||
*'''Brand name:''' Bevyxxa | *'''Brand name:''' Bevyxxa | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 23:35, 31 December 2021
General information
Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/23/2017: FDA approved for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Also known as
- Code name: PRT-054021
- Brand name: Bevyxxa